Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Centessa Pharmaceuticals PLC - - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CNTA
Nasdaq
8731
https://www.centessa.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Centessa Pharmaceuticals PLC -
Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results
- Mar 28th, 2024 10:11 pm
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
- Mar 28th, 2024 8:28 pm
Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares
- Mar 27th, 2024 5:26 am
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
- Mar 19th, 2024 12:01 am
Private equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139m
- Mar 12th, 2024 5:02 pm
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
- Feb 22nd, 2024 1:00 pm
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
- Feb 9th, 2024 12:00 pm
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Jan 22nd, 2024 1:00 pm
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
- Dec 27th, 2023 1:49 pm
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
- Dec 26th, 2023 2:29 pm
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
- Dec 13th, 2023 1:00 pm
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
- Dec 10th, 2023 5:05 pm
Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect?
- Dec 5th, 2023 2:55 pm
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
- Nov 27th, 2023 9:15 pm
Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know
- Nov 16th, 2023 2:55 pm
Centessa Pharmaceuticals PLC Reports Q3 2023 Financial Results and Business Progress
- Nov 15th, 2023 12:28 am
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
- Nov 13th, 2023 9:05 pm
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
- Nov 2nd, 2023 1:09 pm
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
- Oct 31st, 2023 12:00 pm
Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
- Oct 25th, 2023 12:00 pm
Scroll